GAITHERSBURG, MD. (WJZ) — Maryland-based Novavax gave an update Tuesday on Phase Three of its COVID-19 vaccine trial.
The company said Tuesday 5,500 people have enrolled in its clinical trial in the United Kingdom and expect it to be fully enrolled by the end of November.
- TIMELINE: Coronavirus In Maryland, Tracking The Spread
- Latest coronavirus stories from WJZ
- Latest CDC Guidelines
“We are pleased with the significant progress made in our Phase 3 clinical trial since it began in the United Kingdom at the end of September,” said Gregory M. Glenn, M.D., President of Research and Development at Novavax. “We are grateful for the support of the U.K. Government’s Vaccines Taskforce (VTF) and the National Institute for Health Research (NIHR) for our pivotal trial. Recognizing the recent, large increase in the number of COVID-19 cases in the U.K., as well as the rapid progress in participant enrollment for our trial, in consultation with the VTF and NIHR, we adjusted our plans and increased enrollment.”
Novavax expects its U.S. Phase Three clinical trial to begin by the end of November.
Data from the trial is expected as soon as early first quarter 2021, the company added.
Maryland saw an uptick in new COVID-19 cases Tuesday, with nearly 900 more reported.
The state reported 897 new COVID-19 cases, bringing the total to 141,741. Nine more Marylanders have died as a result of the virus, bringing the total to 3,962.
Tuesday marked the first time cases in Maryland have risen above 800 since September 12. It’s also the highest single-day increase since August 9.